#USA #New York #Pomerantz LLP #Actinium #ATNM

Class Action Alert for Actinium Pharmaceuticals Investors

On April 14, 2025, the Pomerantz Law Firm announced an urgent class action lawsuit concerning Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This lawsuit targets investors who have incurred losses on their investments in the company, and it comes with significant deadlines that investors need to be aware of.

Pomerantz LLP, renowned for its expertise in corporate, securities, and antitrust class litigation, is advising affected investors to reach out to them. They can contact Danielle Peyton directly at [email protected] or call 646-581-9980. Additionally, there's a toll-free number for inquiries: 888.4-POMLAW (extension 7980). Investors are strongly encouraged to provide their contact details, including mailing address, phone number, and the amount of shares they acquired during the pertinent timeframe.

Background of the Class Action

The class action primarily revolves around allegations that Actinium Pharmaceuticals and some of its executives have engaged in perpetrating securities fraud and other unlawful business practices. Investors need to act quickly, as there is a deadline of May 26, 2025, to petition the Court for the position of Lead Plaintiff if they purchased or acquired securities in Actinium during the defined Class Period. For those interested, a copy of the complaint can be accessed via the firm’s website at www.pomerantzlaw.com.

Insights on Recent Developments in Actinium

This alert follows recent alarming news concerning the company. On August 5, 2024, Actinium released a press statement about a regulatory update regarding its intended Biologics License Application (BLA) for Iomab-B, a treatment aimed at patients with relapsed or refractory acute myeloid leukemia (r/r AML). In the announcement, the U.S. Food and Drug Administration indicated that the Phase 3 SIERRA trial did not provide adequate evidence to support a BLA for Iomab-B, despite the trial meeting its primary endpoint.

Consequently, this update had a dramatic impact on Actinium's stock price, leading to a drop of $3.69 per share, nearly 60%, with the shares closing at $2.48 on that day. Such price fluctuations highlight the critical nature of the information surrounding the company and the potential implications for investors.

About Pomerantz LLP

Pomerantz LLP has built a strong reputation over more than 85 years, specializing in securing justice for victims of securities fraud and corporate misconduct. Founded by Abraham L. Pomerantz, a pioneer in the field, the firm has consistently fought for shareholder rights and recovered substantial damages for class members. Their ongoing mission remains to uphold the principles established by its founders, ensuring that those affected by corporate malpractice can seek recourse.

As this situation continues to evolve, investors who believe they may have a claim are urged to reach out promptly to explore their legal options. For updates and more information on how to get involved in the class action, investors can also monitor announcements from both the law firm and Actinium Pharmaceuticals itself. It is crucial not to miss any approaching deadlines that could impact any legal pursuits by concerned shareholders.